Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab in Relapsed/Refractory Multiple Myeloma
NCT05535244Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2022
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of cevostamab in multiple myeloma (MM), sponsored by Roche. Started Oct 2022; status: active, not recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05535244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535244.